| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-10-16 |
| タイトル |
|
|
タイトル |
Clinical effects of tacrolimus blood concentrations early after allogeneic hematopoietic stem cell transplantation |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 著者 |
久保, 裕之
今滝, 修
福本, 哲也
石田, 智也
Hamasaki, Yukiko
芳田, 峻典
植村, 麻希子
藤田, 晴之
門脇, 則光
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background aims
Tacrolimus (TAC) plus short-term methotrexate (stMTX) is used for graft-versus-host disease (GVHD) prophylaxis after allogeneic hematopoietic stem cell transplantation (allo-HSCT). TAC blood concentrations are frequently adjusted to enhance the graft-versus-leukemia/lymphoma effect or attenuate severe GVHD. Limited information is available on the clinical impact of these adjustments and the optimal time to perform them in order to achieve good clinical outcomes. |
|
言語 |
en |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Methods
We retrospectively analyzed 211 patients who underwent allo-HSCT at our institutes. |
|
言語 |
en |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Results
Higher TAC concentrations in week 3 correlated with a significantly higher cumulative incidence of relapse (CIR) (P = 0.03) and lower nonrelapse mortality (P = 0.04). The clinical impact of high TAC concentrations in week 3 on CIR was detected in the refined disease risk index: low/intermediate (P = 0.04) and high (P < 0.01), and conditioning regimens other than cyclophosphamide/total body irradiation and busulfan/cyclophosphamide (P = 0.07). Higher TAC concentrations in week 1 correlated with a lower grade 2-4 acute GVHD rate (P = 0.01). Higher TAC concentrations in weeks 2 and 3 correlated with slightly lower (P = 0.05) and significantly lower (P = 0.02) grade 3-4 acute GVHD rates, respectively. Higher TAC concentrations in weeks 1 and 3 were beneficial for severe acute GVHD in patients with a human leukocyte antigen-matched donor (P = 0.03 and P < 0.01, respectively), not treated with anti-thymocyte globulin (P = 0.02 and P = 0.02, respectively), and receiving three stMTX doses (P = 0.03 and P = 0.02, respectively). |
|
言語 |
en |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Conclusions
The clinical impact of TAC concentrations varied according to patient characteristics, including disease malignancy, conditioning regimens, donor sources, and GVHD prophylaxis. These results suggest that TAC management needs to be based on patient profiles. |
|
言語 |
en |
| 書誌情報 |
en : Cytotherapy
巻 26,
号 5,
p. 472-481,
発行日 2024-05-01
|
| 出版者 |
|
|
出版者 |
Elsevier |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
1477-2566 |
| 権利 |
|
|
言語 |
en |
|
権利情報 |
© 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved. |
| PubMed番号 |
|
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
38456854 |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
graft-versus-host disease |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
graft-versus-leukemia/lymphoma effect |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
hematopoietic stem cell transplantation |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
nonrelapse mortality |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
relapse |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
tacrolimus |
Cytotherapy26-5_472-481
